Neuroendocrine Tumors

Neuroendocrine Tumors

Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors

June 15 2 min read
In a French phase II noncomparative trial (OCLURANDOM) reported in The Lancet Oncology, Baudin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) produced numerically better progression-free survival results than those achieved with sunitinib when used as an internal control in patients with previously treated somatostatin receptor–positive metastatic pancreatic neuroendocrine tumors.

Latest in Neuroendocrine Tumors